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Radiotherapy remains a mainstay of cancer treatment, being used in
roughly 50% of patients. The precision with which the radiation dose can
be delivered is rapidly improving. This precision allows the more accurate
targeting of radiation dose to the tumor and reduces the amount of sur-
rounding normal tissue exposed. Although this often reduces the unwanted
side effects of radiotherapy, we still need to further improve patients’ qual-
ity of life and to escalate radiation doses to tumors when necessary. High-
precision radiotherapy forces one to choose which organ or functional
organ substructures should be spared. To be able to make such choices, we
urgently need to better understand the molecular and physiological mecha-
nisms of normal tissue responses to radiotherapy. Currently, oversimplified
approaches using constraints on mean doses, and irradiated volumes of
normal tissues are used to plan treatments with minimized risk of radiation
side effects. In this review, we discuss the responses of three different nor-
mal tissues to radiotherapy: the salivary glands, cardiopulmonary system,
and brain. We show that although they may share very similar local cellu-
lar processes, they respond very differently through organ-specific, nonlocal
mechanisms. We also discuss how a better knowledge of these mechanisms
can be used to treat or to prevent the effects of radiotherapy on normal tis-
sue and to optimize radiotherapy delivery.
1. Introduction
The number of new cancer cases per year is estimated
to rise to 22.2 million by the year 2030 worldwide [1],
and about 12 million patients will receive radiotherapy
as part of their treatment [2,3]. Although radiotherapy
is well tolerated by most patients, some experience
radiation-induced side effects, the severity and
frequency of which can be reduced by modern, more
precise therapies, such as particle therapy and
advanced image-guided technologies. This improved
precision can be used to minimize the radiation dose
to normal tissue thereby reducing side effects, but can
also be used for escalation of dose to poorly respond-
ing tumors without increasing the risk of side effects.
Abbreviations
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Currently, oversimplified approaches using con-
straints on mean doses and irradiated volumes of nor-
mal tissues receiving a specified dose are used to plan
treatments with minimized risk of radiation side
effects. Initially, consensus publications such as the
Emami paper were the main sources for constraints
[4]. More recently, these have been updated by system-
atic literature reviews, such as the one performed in
the Quantec effort [5].
Modern radiotherapy techniques, such as intensity-
modulated radiotherapy (IMRT) and volumetric mod-
ulated arc therapy (VMAT) (Box 1), reduce the
amount of normal tissue that receives a high dose of
radiation but at the cost of large volumes of tissue
receiving a low dose. In contrast, particle therapy
(Box 1) allows to concentrate a high dose of radiation
to the tumor while limiting the integral dose to normal
tissues. As such, modern radiotherapy technologies
offer greater precision but their optimal use requires
radiation oncologists to have a better understanding of
how these therapies affect normal tissue.
2. Radiation-induced side effects
Radiation activates a damage repair cascade in nor-
mal tissues. This cascade initiates with the DNA
damage response that includes apoptosis, mitotic cell
death, and cellular senescence [10], and is followed by
a perpetual cytokine cascade, which induces inflam-
mation and excessive extracellular matrix (ECM) and
collagen deposition, processes that are largely modu-
lated by reactive oxygen and nitrogen species (ROS/
RNS) imbalance and tissue hypoxia [11]. The side
effects of radiotherapy in normal tissue can be
divided into early (or acute) and late responses,
depending mostly on tissue turnover time and their
modulation by processes that mimic a wound healing
response [11]. Early (or acute) side effects occur dur-
ing, immediately after, or soon after (within weeks
of) radiotherapy treatment [11,12]. Early side effects
are often reversible when the dose is limited and tis-
sue turnover is high, such as in the oral mucosa [13]
and gut, or partly reversible, such as in lungs
Box 1
Radiotherapy techniques
From the 90s until today, radiotherapy has undergone a strong technological development aimed at improving precision
of radiation dose delivery to the tumor while minimizing the dose to the normal tissue. By the end of the 90s, 3-
dimensional conformal radiotherapy (3DCRT) was introduced. In this technique, 3D imaging data prior to treatment are
used to design a limited number of radiation beams with a fixed shape and uniform dose distribution matching the shape
of the tumor volume. During the first decade of this century, this technique was enhanced into IMRT, which allows
variations of dose within each beam, thus providing a new dimension of optimization. Typically IMRT also uses more
beams than 3DCRT allowing a more conformal dose distribution. In the past decade, this was further developed into
techniques irradiating while rotating the irradiator around the patient in VMAT. This technique results in arcs rather
than discrete beams. Though technically all of these modalities use anatomical and more recently also functional
information obtained before the start of treatment, utility of imaging obtained during the treatment was recognized. The
use of such imaging is termed image-guided radiotherapy. In parallel to the development of these photon-based
irradiation techniques, particle therapy, which is based on the use of ions, such as protons in proton therapy or carbon
ions, can offer opportunities to further reduce the radiation dose to the normal tissue. In contrast to photons, particle
therapy aims to achieve radiation dose deposition concentrated predominantly at a precise depth by exploiting the
intrinsic physical properties of ions. This allows additional sparing of the normal tissue.
The risk of side effects on normal tissue depends on the radiation dose and the volume of normal tissue irradiated [6].
Recently, it has been shown that volume effects can be region-dependent [7] and can even involve interactions between
different organs [8,9]. Recent technologies might, for the first time, allow treatments to be optimized by taking into
account such intra-organ variations in sensitivity and interorgan interactions. In this review, we show that such
optimization requires knowledge of the tissue and organ-level mechanisms that are responsible for such regional
variations and organ interactions. To this end, we address different aspects of the mechanisms of radiation-induced
normal tissue effects in general and more specifically of the salivary glands, cardiopulmonary system, and brain. These
three organs exhibit similar local cellular responses but nevertheless differ strongly in their response to radiotherapy due
to fundamental differences in tissue organization and in the consequences of tissue damage for their function. We discuss
these consequences, focusing on their implications for the prevention and treatment of radiation-induced side effects.
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(pneumonitis) [14], skin [15], and brain (memory loss
and fatigue [16]).
Late normal tissue side effects are defined by their
occurrence several months to years after radiotherapy
[11,12]. Late side effects are in general chronic and
often progressive, leading to a reduction in patients’
quality of life following treatment. These are, there-
fore, often employed to determine radiation dose limits
[11]. In contrast to early side effects, the time to
response of late-responding tissues depends on the
dose and is modulated by processes such as cellular
senescence, chronic inflammation, hypoxia, and fibro-
sis [11]. All of these responses subsequently inhibit the
regenerative potential of the tissue. Importantly, fibro-
sis is involved in the pathogenesis of side effects in
most tissues, such as heart [17], lung [14], and liver
[18].
Although different normal tissues may share very
similar localized cellular processes, they may respond
very differently owing to organ-specific, nonlocal
mechanisms, such as loss of peripheral tissue sec-
ondary to loss of stem cells located in specific regions
and functional dependence between organs. In the fol-
lowing sections, we describe such responses for three
different tissues, the salivary gland, lung, and brain.
We also illustrate how these responses can offer
unique opportunities for therapeutic and preventative
strategies.
3. Salivary glands
Most head and neck cancer (HNC) patients are treated
with radiotherapy alone, or in combination with
chemotherapy and/or surgery. This often results in the
unavoidable co-irradiation of the peripherally posi-
tioned salivary glands. Forty percent of HNC patients
receiving IMRT will experience moderate or severe
xerostomia (‘dry mouth syndrome’), resulting from
hyposalivation, leading to alterations in speech and
taste, difficulties with mastication and deglutition, and
an increased risk of developing oral infections and
dental caries [19–21]. These sequelae severely hamper
the quality of life of affected patients.
3.1. Cellular and tissue responses over time
Salivary glands contain saliva-producing mucous and
serous acinar cells, myoepithelial cells, duct cells,
cholinergic and adrenergic nerve fibers, blood vessels,
and supporting stromal tissue [22,23], which can all be
affected by irradiation. Interestingly, although salivary
gland parenchymal cells are mostly postmitotic with a
cell turnover time of 60–120 days, their response to
radiation is acute as observed both in rodents [24] and
in humans [25] and is followed by a later response,
which is induced by different mechanisms [26,27]
(Fig. 1). The early response cannot be due to mitotic
failure and has been attributed to several abnormalities
in murine and rhesus monkey: the apoptosis of acinar
cells [28,29], the membrane damage-induced dysfunc-
tion of acinar cells [24,26], the impairment of
microvessels [30], and reduced parasympathetic signal-
ing [31]. A major characteristic of late radiation-dam-
aged salivary glands is the accumulation of chronic
inflammation and fibrosis and consequent tissue dys-
function and atrophy [11,24] (Fig. 1). This coincides
with a lack of regenerative potential of salivary gland
stem/progenitor cells (SSPCs) [32]. Indeed, the radia-
tion-surviving SSPCs in and outside of the radiation
field have been shown to determine the regenerative
capacity of the gland post-treatment [32,33]. Interest-
ingly, senescent cells accumulate in the murine salivary
gland ducts [34], where SSPCs seem to reside [32].
These senescent cells develop a unique secretory phe-
notype, called senescence-associated secretory pheno-
type (SASP). The SASP includes several
proinflammatory and profibrotic growth factors [10]
and is associated with reduced tissue regenerative
capacities, inflammatory processes, and fibrosis [35]. In
rodent models, acini have been shown to have some
regeneration capacity even 1 year after treatment, as
large acinar cell clusters have been found in irradiated
salivary gland tissues (Fig. 1) [36,34]. This is probably
due to acinar cell proliferation. However, the resulting
clusters do not seem to be functional [36]. While there
is relative consensus in the field regarding the late
effects of radiation on salivary glands, there is less
clarity about the early effects, which depend on the
preclinical model used. The salivary glands of different
rodent species and strains respond quite differently to
irradiation. FVB mice [38] and Wistar rats [26–28]
have a clear early response [38], whereas C57BL/6
mice have a relatively mild early response but a strong
late response [39]. Additionally, different radiation
dose tolerance and responses depend on whether the
radiation field is localized or includes the whole head
[40].
3.2. Therapeutic approaches
Our increased level of understanding of radiation-in-
duced damage has led to a multitude of therapeutic
strategies to ameliorate salivary gland radiation dam-
age. These have recently been reviewed by Jensen et al.
[41], here, we focus on some that are related to the
above-described mechanisms.
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Many radical scavengers have been tested in a vari-
ety of models. ROS/RNS scavengers aim to reduce the
effective radiation dose to the tissue, thereby poten-
tially sparing normal tissue cells but not the tumor.
One such scavenger is amifostine, which in rat salivary
glands shows amelioration of function loss depending
on the irradiated region in rat salivary glands [42] and
improved protection when it is injected in a retrograde
manner in the secretory ducts [43], where SSPCs seem
to be located [32]. However, amifostine clinical trials
have been inconclusive, owing to limited statistical
power or a lack of proper control arms [41]. In addi-
tion, amifostine has serious side effects at the moment
of administration, such as nausea, and probably can-
not be administered in the effective dose range used in
animal experiments [44]. An alternative with less side
effects could be tempol, which has been shown to pro-
tect the murine salivary gland and not the tumor [45].
Other strategies have been developed to optimize the
salivary gland’s regenerative potential after radiother-
apy. Most of these treatments stimulate the prolifera-
tion of the remaining SSPCs, limiting their use to
(parts of) the tissue that have received a relatively low
dose [46]. These approaches encompass both pharma-
cological agents that stimulate the parasympathetic
response of the gland, such as pilocarpine, and growth
factors that stimulate proliferation [46]. The saliva
secretion inducing sialagogue, Pilocarpine, has been
relatively well studied, both as a treatment before and
after radiotherapy. Animal and human studies show
that this drug produces some improvement in salivary
flow, which seems again to be limited by the maximum
dose received [47,48] and which probably relies on
improving the proliferation of the remaining radiation-
surviving cells [49]. Similarly, growth factors, such as
insulin growth factor 1 [50], keratinocyte growth factor
[51], as well as cytokine producing mesenchymal stem
cells (MSCs), have been shown to improve salivary
gland function after relatively low-dose irradiation by
stimulating the proliferation of radiation-surviving
cells. MSCs derived from different sources, such as
bone marrow or adipose tissue, have been associated
with the regeneration of radiation-damaged normal tis-
sues [52] including salivary glands [53,54]. A recent
phase I/II clinical trial has shown the clinical feasibility
and a marginal effect of such a therapy in the treat-
ment of postradiotherapy hyposalivation [55]. How-
ever, since MSCs do not transdifferentiate into
salivary gland cells but rather stimulate remaining sur-
viving cells to proliferate, their action depends on the
Fig. 1. A schematic of the cellular and tissue responses of the salivary gland to radiotherapy over time. (Left panel) The left panel depicts a
model of a salivary gland and shows the structure of the acinus, which when enlarged features the different cell types it is composed of.
(Right panel) The early and late responses of salivary gland tissue to radiotherapy. The early response (which occurs within hours or days) is
completely different mechanistically to the late response. The early response is too rapid to be explained by mitotic failure or related cell
death and seems to be due to failure of vasculature function, parasympathetic nerve function, acinar cell signal transduction, and possibly
inflammation and acinar cell apoptosis (which is limited, depending on the experimental model used). The later effects (which occur
> 30 days after radiotherapy) result from acinar cell loss, which coincides with chronic inflammation and fibrosis. Depending on the
radiotherapy dose used, some morphological recovery might follow, as shown by the appearance of acinar cell clusters.
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number of surviving SSPCs and their effect might be
limited to the lower radiation dose regions [46]. Inter-
estingly, MSCs have been shown to remodel radiation-
induced fibrosis [52]. Therefore, sequential or com-
bined treatment with senolytics, drugs that kill senes-
cent cells, and MSCs might improve the radiation-
damaged salivary gland environment for transplanta-
tion. The dependence of such therapies on the viability
of remaining stem cells demands new research to
enhance the number of surviving SSPCs.
Stem cell-based therapy may provide a means to
reduce radiation-induced hyposalivation in patients
after radiotherapy treatment [32]. Recently, we have
shown the potential of stem cell therapy to amelio-
rate radiation-induced hyposalivation in mice using
expanded murine and human autologous adult
SSPCs [56–58]. Interestingly, the positive effect of
human SSPCs was partially due to the remodeling of
the tissue [58]. SSPCs, however, cannot be obtained
from patients with late radiation toxicity. A solution
for this would be to use episomal reprogrammed
somatic cells, such as blood mononuclear cells [59],
that can generate pluripotent stem cells (PSCs),
which are able to differentiate into every cell type in
the body [60]. Similarly, embryonic stem cells (ESCs)
have recently been shown to be able to differentiate
into salivary gland cells [61], opening up novel ave-
nues for regenerative medicine. A stem cell-based
approach to treating the side effects of radiotherapy
on normal glands might be most effective when com-
bined with the remodeling of the radiation-damaged
salivary gland environment.
3.3. Preventing radiation-induced damage of
salivary glands
Knowing where SSPCs are localized could help to pre-
vent radiation-induced salivary gland dysfunction. We
have shown that the stem cells of the rodent and
human parotid salivary gland localize to a specific
region where the main excretory ducts are [7]. Sparing
this region from radiation during radiotherapy for
HNC is currently being evaluated in a double-blind
randomized clinical trial [62], with promising prelimi-
nary results. However, the complete sparing of the
area that contains the highest proportion of SSPCs
proved to be difficult due to the close vicinity of the
tumor. This and the finding that these stem/progenitor
cells might be very sensitive to low doses of irradiation
[63] warrant the use of very accurate radiotherapy
technologies, such as proton therapy (Box 1). The
above-described approaches have all been developed
after obtaining a deeper knowledge of the response of
the salivary gland to irradiation. Expanding this
knowledge might, in the future, result in patient-speci-
fic approaches that can prevent or ameliorate radio-
therapy-induced hyposalivation.
4. Cardiopulmonary system
Treatment of thoracic cancers with radiotherapy can
cause side effects. Traditionally, early pulmonary and
late cardiac damage has received the most attention
[64]. The clinical sequelae of radiation lung injury usu-
ally start with the acute onset of radiation pneumonitis
at 2–6 months after radiotherapy with symptoms that
range from cough, fever, and dyspnea to even death
from respiratory failure. Radiation-induced lung fibro-
sis often develops subclinically from several months to
years after radiotherapy. In rodents, symptoms of toxi-
city manifest as increased breathing frequency [65–67].
Several inflammatory responses initiated by radiation
and radiation-induced damage contribute to radiation
pneumonitis [68,69]. Acute alveolar and interstitial
inflammation leads to the loss of type I epithelial cells
and endothelial cells, while inducing the proliferation
of type II epithelial cells. These events initiate a cas-
cade of inflammatory cytokines, which plays an impor-
tant role in radiation pneumonitis [70]. This can be
aggravated by combined treatment with chemothera-
peutic agents [70]. Furthermore, beginning at 4 weeks
after irradiation, an increase in ECM collagen deposi-




Pneumonitis: inflammation of lung tissue.
Radiation pneumonitis: pneumonitis caused by radiation.
Episomal reprogramming: system that reprograms so-
matic cells into induced PSCs, which are able to
differentiate into almost any type of cell in the body.The
risk and severity of lung radiation side effects depend on
the dose and volume of the tissue involved [65,72–74].
Therefore, technical advances that enable treatment
optimization are currently used to reduce dose and
volume of normal tissue receiving radiation.
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4.1. Cellular and tissue responses
In the 1990s, Travis et al. [75] hypothesized and con-
firmed that the consequences of irradiating the lung
might vary depending on which part of the lung was
irradiated. Their studies in mice found that responses
to the irradiation of basal subvolumes of the lung were
consistently more severe than those observed after the
irradiation of apical subvolumes. Based on these
results, they hypothesized that this variation originated
from a nonuniform distribution of alveolar tissue over
the lung [76]. The latter hypothesis was indeed con-
firmed in rat studies, in which irradiation of the lateral
parts of the lungs resulted in more severe respiratory
dysfunction than did irradiation of the medially
located parts of the lung that also contain the major
airways [66]. However, interestingly in the same model,
it was also observed that part of the regional variation
in response could be explained by variations in dose in
the heart [9,77]. Although also in patients a regional
variation in the risk of radiation pneumonitis was
observed, the data cannot distinguish between a role
of alveolar distribution and involvement of the heart
[78].
Since the heart and lungs are linked by the car-
diopulmonary circulation, it was hypothesized that
damage in these two organs after radiotherapy is medi-
ated by changes in the cardiopulmonary circulation.
Indeed, in rats it was found that heart irradiation
reduced left ventricle diastolic function, leading to
signs of congestion in the lungs that closely resembled
the classical signs of radiation pneumonitis, such as
shortness of breath, inflammation, and fibrosis [8].
Interestingly, also in rats it was shown that lung irradi-
ation damages the endothelial cell (EC) layer of the
pulmonary microvasculature within the first 2 weeks
after irradiation, which precedes parenchymal damage
[79]. These damages occur both in irradiated and
spared lung tissue [79]. It was suggested that irradia-
tion induces EC loss and that this leads to a contrac-
tion of the vasculature, which subsequentially results
in an increase in pulmonary pressure in the unirradi-
ated part of the lung. This increased pressure induces
the sheering of ECs, much like that observed in
Fig. 2. A schematic of the side effects of radiotherapy on the cardiopulmonary system over time. Shown are the cellular, tissue, and organ
responses over time in the tissues of the lung and heart. The loss and dysfunction of lung vascular ECs are the first visible forms of
damage in the irradiated lung. This is followed by acute inflammation and, depending on the dose, the first signs of fibrosis. These local
processes are aggravated by loss of diastolic function if the heart is irradiated concomitantly. In the subsequent months, lung damage
progresses and features chronic inflammation and function-limiting fibrosis. The resulting dyspnea might resolve at later time points by
compensatory inflation of nonirradiated parts of the lung. The adequacy of this compensatory response, however, depends on the irradiated
lung volume. In addition, cardiac irradiation might also lead to later onset cardiac failure.
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pulmonary hypertension models [80,81]. EC injury
might initiate or mediate structural changes in pul-
monary vasculature, as described for pulmonary
hypertension [82,83]. Indeed, pronounced vascular
remodeling, including muscularization, adventitia
thickening, and neointima formation throughout the
lungs, was observed to result in increased pulmonary
vascular resistance, leading to pulmonary hypertension
[8,79]. The pathological features of the pulmonary vas-
culature were highly specific for pulmonary arterial
hypertension. Pulmonary arterial hypertension can also
impair left ventricle function, further aggravating the
symptoms of cardiopulmonary dysfunction [8]. These
effects depend on the irradiated lung volume, possibly
pointing to a critical role for the amount of irradiated
vasculature in the etiology of cardiopulmonary dys-
function [79]. As a consequence, limiting the irradiated
volume may be more effective in preventing cardiopul-
monary dysfunction than reducing the radiation dose
within irradiated volumes.
Interestingly, cardiac irradiation has also been
shown in a rat model to cause early interstitial and
perivascular fibrosis of the heart in combination with
loss of diastolic function [8]. Loss of diastolic function,
and its associated congestion in the pulmonary circula-
tion, increases the risk of cardiopulmonary dysfunc-
tion. When combined with pulmonary hypertension,
loss of diastolic function increases the risk of cardiac
failure [8].
In the ongoing CLARIFY study, the occurrence
and impact of these and potentially other disturbances
of cardiopulmonary physiology on patients are cur-
rently studied in a large prospective cohort study in
lung and esophageal cancer patients using pre- and
post-treatment echocardiography, cardiac magnetic
resonance imaging, and blood biomarkers [84].
These findings indicate that in the development of
radiation damage, the heart and lung must be consid-
ered as an integrated system. This broader view of
integrated responses of organs and organ systems pro-
vides us with novel opportunities to optimize radio-
therapy treatment, as well as treatment of toxicity.
Firstly, the functional interaction that exists between
the heart and lung calls for the combined dose distri-
bution in both organs to be optimized for the underly-
ing systemic changes. Secondly, the process underlying
the interaction between heart and lung provides novel
targets for interventions to prevent toxicity.
4.2. Therapeutic approaches
Multiple approaches have been explored to reduce pul-
monary toxicity but very few have been used in the
clinic. Nevertheless, the mechanisms described above
could inform the development of novel preventive or
treatment measures.
For the nononcological patient, the prolonged acti-
vation of the renin–angiotensin–aldosterone system
(RAAS) plays an important role in the progression of
cardiac failure [85]. Consequently, inhibiting various
components of the RAAS is a cornerstone of current
treatments for heart failure [85,86]. The inhibition of
angiotensin-converting enzyme (ACE) to prevent the
conversion of angiotensin I into angiotensin II and the
activation of downstream mechanisms has been the
most common approach used to achieve this.
Cardiac irradiation causes loss of diastolic function
with detrimental consequences for the lung, as
observed in a rat model [8,87]. Given this, could ACE
inhibition be a promising strategy by which to reduce
or prevent the failure of the cardiopulmonary system
after thoracic radiotherapy? This does indeed appear
to be the case. In a rat model, the ACE inhibitor, cap-
topril, was observed to reduce dyspnea after whole-
thorax irradiation [88,89]. In experiments where radia-
tion doses in heart and lung were varied in a con-
trolled manner, this effect was shown to be likely
achieved by reducing interstitial and perivascular fibro-
sis in the heart, leading to the preservation of diastolic
function [87]. These results suggest that the RAAS is
indeed involved in the development of radiation-in-
duced loss of diastolic function. Moreover, this finding
suggests that treatments for conditions that lead to
cardiac failure in nononcological patients might be
potentially useful for preventing radiotherapy-induced
cardiopulmonary complications.
4.3. Preventing radiation-induced damage in the
cardiopulmonary system
As indicated, research on the regional responses of the
lung was inspired by the idea that such regional
responses might offer opportunities to reduce, or even
prevent, normal tissue toxicity by avoiding the most
important regions of the lung [75]. Indeed, this idea
led to clinical studies in which risk estimation
improved, the use of lung doses was replaced by a
hybrid model that incorporated the local function of
the lung and that optimized treatment strategies by
avoiding vital lung tissue. This was achieved by mov-
ing the radiation dose to parts of the lung with a lower
contribution to function [90].
However, as described in the previous section, recent
animal work illustrates that cardiac and pulmonary
toxicity can no longer be seen as separate entities and
that both organs need to be spared. Unfortunately, the
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ability of photon-based treatment technology to
achieve this is limited due to dose deposited beyond
the tumor volume. Interestingly, the peaking of the
dose distribution of particles near the end of their pen-
etration depth and the lack of dose beyond is expected
to offer unprecedented opportunities to achieve this
[91,92].
5. Brain
Radiotherapy-induced neurocognitive dysfunction rep-
resents the major side effect of cranial radiotherapy in
adult and pediatric cancer survivors, affecting school
performance, employment, and independent living [93].
The brain is mostly formed by postmitotic neurons
and glial cells. Glial cells primarily consist of the fol-
lowing cell types: astrocytes, which support neuronal
function;oligodendrocytes, which are responsible for
coating axons with myelin; and microglia, which are
the resident macrophages of the brain. The brain also
harbors a limited number of neural stem and progeni-
tor cells in two restricted regions of adult neurogenesis.
Importantly, the brain is isolated from the rest of the
body’s bloodstream by the blood–brain barrier (BBB),
which is formed of highly selective junctions between
ECs. Although it is difficult to dissect the contribution
of each cell type and their interaction to the pathogen-
esis of the neurocognitive dysfunction that occurs as a
late response (> 4 months) after radiotherapy, these
cell types have been shown to be all somehow affected
by radiation (Fig. 3).
5.1. Cellular and tissue responses over time
Endothelial cells form the inner layer of blood vessel
walls and, together with mural cells and astrocytes,
ensure cerebral blood flow and BBB integrity [94].
Within hours after irradiation, in rodent models, ECs
apoptose in a p53-independent manner via the acid
sphingomyelinase pathway, leading to the early disrup-
tion of BBB permeability [95,96]. This is followed, at
1–3 months after irradiation, by the irreversible dis-
ruption of the BBB, which is linked to persistent
inflammation modulated by tumor necrosis factor
(TNF)-alpha and vascular endothelial growth factor
(VEGF) overexpression in the astrocytes surrounding
the ECs [97]. This delayed response is often restricted
to white matter regions and precedes the development
of radiation-induced necrosis.
As in the salivary gland, the adult brain contains
slowly proliferating stem and progenitor cells. Neuro-
genesis in the adult mammalian brain primarily occurs
in two regions, the subventricular zone (SVZ) adjacent
to the lateral ventricles and the subgranular zone
(SGZ) in the dentate gyrus of the hippocampus.
Within hours after irradiation, ataxia-telangiectasia
mutated (ATM) and p53-dependent apoptosis of neu-
ral progenitor cells is observed in the SVZ [98,99] and
in the SGZ region of rodent models [100]. In the
longer term (> 2 months postirradiation), a change in
cell fate differentiation from a neuronal to a glial fate
is also observed [100]. This delayed response seems to
be due to changes in the stem cell niche microenviron-
ment, which include elevated levels of activated micro-
glia and a disrupted vasculature that affects the
regenerative potential of the remaining stem cells [100].
Glial cells include oligodendrocytes, astrocytes, and
microglia. Oligodendrocyte progenitor cells (OPCs) in
rodent models, similar to the progenitor cells of the
SVZ and SGZ regions, have been shown to apoptose
hours after irradiation. This in the long-term
(> 4 months postirradiation) results in the irreversible
depletion of mature myelinating oligodendrocytes,
leading to white matter damage [101,102]. This effect
seems to be partially mediated by the upregulation of
VEGF by reactive astrocytes in proximity to white
matter regions [103]. Astrocytes and microglia in
rodent models have indeed been shown to similarly
respond to radiation with an initial (within hours)
overexpression of TNF-alpha and other cytokines,
leading over time to chronic neuroinflammation char-
acterized by reactive astrogliosis and subsequent
microglial activation lasting for years after irradiation
[104,105].
Despite being the largest cell population in the
brain, a limited number of studies have focused on
the direct impact of radiation on postmitotic neu-
rons. Extensive changes in mouse neuronal dendritic
and spine morphology have been reported after
doses of 1 to 10 Gy, starting as early as 10 days
after irradiation and progressively worsening there-
after [106]. Among the different types of dendritic
spines, early filopodia membranous protrusions were
most sensitive to radiation, thus possibly hindering
their development into mature dendritic spines. These
morphological changes were accompanied by a
decrease in the presynaptic marker synaptophysin,
followed by an upregulation of the synaptic protein
PSD-95. Abnormal glutamate signaling (as early as
1 h after irradiation with 10 Gy) has been proposed
as being a contributing factor to radiation-induced
synaptic changes that lead to excitotoxicity by exces-
sive synaptic stimulation [107]. However, how radia-
tion directly impacts the dendritic spines remain to
be fully elucidated and other intermediated responses
are likely mediating this effect. Additionally, whether
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all of the above responses faithfully recapitulate what
is occurring in the human brain after radiotherapy
treatment still remains unanswered.
5.2. Therapeutic approaches
Many therapeutic strategies have been explored pre-
clinically in the quest to ameliorate the radiotherapy-
induced neurocognitive sequelae. For example, in rats,
the PPAR-gamma agonist, pioglitazone, and the ACE
inhibitor, ramipril, have been shown to indirectly
improve neurocognitive dysfunction, although without
directly improving the already damaged brain vascula-
ture [108–110]. In patients with brain tumors, pioglita-
zone and ramipril have been, or are currently being,
tested in phase I and II clinical trials [111] (ClinicalTri-
als.gov Identifier: NCT03475186).
Fig. 3. A schematic of the cellular and tissue responses of the brain to radiotherapy over time. Radiation causes multiple effects in the
brain, including vascular damage, neurogenesis decline, white matter damage, and neuronal damage. Within hours after irradiation, cell
death, largely via apoptosis, occurs in ECs, progenitor cells, and neuroblasts of the SVZ and SGZ, and in OPCs. Neurons exhibit abnormal
glutamate signaling and synaptic function relatively early after irradiation, alongside alterations in dendritic spines and morphology. These
early responses are followed by an inflammatory response that is characterized by the release of cytokines, and the reactivity of astrocytes
and microglial cells. This inflammatory response can contribute to both early and late effects that affect different cell types and their
interactions.
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With the goal of improving tissue regeneration, stem
cell transplantation therapies have also been explored
in the brain. Preclinical studies using either human
embryonic or neural stem cells in rodent models have
demonstrated the ability of these cells to integrate in
the brain and to differentiate into neurons and glial
cells, leading to improved neurocognitive function
[112,113]. The underlying mechanisms of this benefit
are not fully established and seem to not be limited to
the replacement of the lost or damaged cells but rather
to include the microvesicle-mediated release of trophic
factors (such as glial cell line-derived neurotrophic fac-
tor, GDNF, and basic fibroblast growth factor, FGF)
by the transplanted stem cells themselves [114]. Intra-
nasally delivered human MSCs have also been used
and have recently been shown to effectively improve
neurocognitive function after irradiation in mice, con-
ferring protection against several responses, including
radiation-induced persistent cAMP response element-
binding (CREB) activation, inflammation, oxidative
stress, and neuronal loss [115].
Pharmacological interventions using food and drug
administration-approved psychiatric medications have
also been explored as possible ways to reduce the long-
lasting impact that radiation has on adult neurogenesis.
For example, in mice lithium [116] has been shown to
reduce apoptosis of neural stem and progenitor cells in
the SGZ, and in rodent models melatonin has been
shown to increase the engraftment of neural stem cells
in the SVZ [117,118]. Running-based exercise has also
been shown to improve neurogenesis in mice after irradi-
ation [119]. The underlying mechanisms of how these
pharmacological and physical interventions increase neu-
rogenesis, however, remain to be fully elucidated and
yet to be confirmed in patients.
A promising preclinical strategy to overcome radiation-
induced white matter damage is the transplantation of
human embryonic stem cell-derived OPCs into the corpus
callosum and cerebellum of irradiated rats [120]. This was
shown to lead to an improvement in neurocognitive and
motor functions. However, the clinical translation of such
an approach remains challenging. In mice, the depletion
of microglia using PLX5622, a dietary inhibitor of col-
ony-stimulating factor-1 receptor (CSF1R), was shown to
prevent radiation-induced neurocognitive dysfunction
[121]. Other interventions to reduce glial cell reactivity
have focused on reducing inflammation using nons-
teroidal anti-inflammatory drugs or selective inhibitors of
proinflammatory cytokines.
In terms of neuronal damage, the administration of
memantine, which blocks the glutamate receptor
NMDAR, in mice just before irradiation prevented
some of the radiation-induced synaptic alterations
[107]. Clinically memantine has been shown to
improved neurocognitive function over time in patients
receiving whole-brain radiation therapy [122].
5.3. Preventing radiation-induced damage in the
brain
One strategy to prevent radiation-induced side effects
is to physically minimize the dose and volume of irra-
diated normal brain tissue or to minimize the exposure
of specific brain structures to irradiation. This can be
achieved using modern radiotherapy technologies, such
as particle therapy. Our current knowledge of the
potential role of different neuroanatomical structures
in the pathogenesis of radiotherapy-induced neurocog-
nitive decline is largely limited to the hippocampus
and its memory function [93]. However, other brain
structures are likely to contribute to the complex neu-
rocognitive sequelae that occur after radiotherapy,
especially in pediatric patients, in whom a large pro-
portion of tumors are located in the posterior fossa
[123]. Future preclinical and clinical efforts should
focus on discerning the contribution of different brain
structures to radiation-induced neurocognitive dys-
function in order to make optimal use of increasingly
advanced radiotherapy technologies.
Another area that is little understood is the contri-
bution of genetic variation to neurocognitive outcome.
This topic has been recently reviewed in Ref. [124].
Strikingly, and possibly due to methodological issues,
very little research has focused on trying to identify
genes that are specifically associated with the develop-
ment of radiotherapy-induced neurocognitive dysfunc-
tion, with only one study showing a potential role for
nitric oxide synthase 3 (NOS3) 894Thomozygosity
[125]. Future research on the contribution of germline
mutations, as well as the role of tumor genetic varia-
tion, is urgently needed to identify those patients who
are most at risk of developing neurocognitive impair-
ment and to offer them personalized preventive or
therapeutic options.
6. Concluding remarks
In this review, we have discussed how recent develop-
ments in understanding how radiotherapy causes toxic-
ity in normal tissue can be understood by describing
three normal tissues at risk of such toxicity. The
increasing availability of high-precision radiotherapy is
changing the way that we look at its effects on normal
tissue. Changes to dose distribution and our increasing
knowledge of the local and nonlocal effects of radio-
therapy on normal tissue warrant the use of a different
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approach to prevent and/or to treat these effects. One
of the commonalities of the three tissues described in
this review is the occurrence of (micro-) vascular
effects. These effects have been described in many tis-
sues but have received relatively little attention when
compared to inflammatory processes and fibrosis.
Since vascular effects might result in volume-depen-
dent within-tissue and between-tissue responses, the
incorporation of such mechanisms in dose distribution
planning would improve treatment outcomes. Such a
strategy, however, requires quantitative information on
the associated responses in patients that can only be
obtained in translational clinical studies, such as our
ongoing study into cardiopulmonary toxicity (acronym
CLARIFY) [84]. Another effect, possibly one that is not
independent of the vascular effect, is the stem cell region-
dependent regenerative potential of some normal tissues.
Here also, altering dose distributions and sparing region
that contain stem cells (as described in the salivary gland
and brain) might also result in the further optimization of
radiotherapy. Sparing or reducing the dose that somatic
stem/progenitor cells are exposed to could result in the
recovery of even late-responding tissues. Their subsequent
stimulation, using cytokines or MSCs, could further
improve the regenerative potential of, and prevent excess
damage to, normal tissue. In addition, regenerative thera-
pies, based on the replacement of the damaged tissue-
specific stem/progenitor cells, might provide a means by
which to further optimize the regenerative potential of the
irradiated tissue. Recently, the development of in vitro tis-
sue resembling models, such as organoids and organs-on-
chip, derived from human tissue-specific adult stem cells
and from ESCs/PSCs and containing different cell types,
including stem/progenitor cells and specialized differenti-
ated functional cells [126], open up endless possibilities for
modeling radiation-induced side effects.
A deeper knowledge of the mechanisms that under-
lie normal tissue damage might also help to develop
better preventive and therapeutic strategies. We need
to progress from understanding local molecular/cellu-
lar events toward having a better understanding of tis-
sue and organ interactions; this progress does not
occur automatically and needs to be supported by sub-
sequent translational research using animal models or
tissue resembling models [63,127]. Typically, studies of
the importance of different structures, in particular for
the adult and pediatric brain, are needed to define
(functional) structures that need to be spared or that
can tolerate a somehow larger dose. Moreover, these
structures are very likely to be interacting with each
other, hence increasing the complexity of such studies.
The most optimal animal models should also be used
to address specific research questions. Although mice
are more available and amenable to genetic manipula-
tion, they might be too small to achieve accurate irra-
diation fields and are also characterized by significant
differences in responses between strains. Rats or even
larger experimental animals might be needed to design
preclinical studies to test the optimal use of modern
radiotherapy technologies. Genetic clinical studies to
identify those patients that are most at risk of develop-
ing late side effects (although not reviewed here) are
certainly of importance and, when possible, should be
validated in combination with animal studies consider-
ing the above-described principles.
The here-described therapeutic and preventative
strategies warrant further translation; however, many
have yet to reach the clinic. The progress of an idea
from the laboratory to the clinic and back to the labo-
ratory to address further questions requires a well-con-
nected multidisciplinary team, which regretfully is
often lacking within one institute. Alongside this, it
seems that findings from well-controlled experiments
in animal models optimized for specific targets are very
difficult to mimic in clinical studies that involve a
diverse group of patients, who are often suffering from
underlying diseases. Obtaining insight into the poten-
tial relevance of preclinical ideas using small clinical
proof-of-concept studies, such as the MRI-HART
study [128], which precedes the much larger ongoing
CLARIFY study [84], is essential for optimizing the
design of clinical studies and for maximizing the prob-
ability that preclinical findings will reach clinical prac-
tice. However, such translational paths require long-
term commitments from both the laboratory and the
clinic. Offering opportunities or work settings that
allow a better understanding of each other’s fields, for
instance, by spending internships in the laboratory or
in the clinic, may help to achieve this.
Although the translation of preclinical research
remains a challenge, several of the above-described
research discoveries are slowly entering the clinic. Stem
cell-sparing trials, such as the one described in Ref.
[62], are currently being performed and some stem cell
therapies are close to or in phase I/II clinical trials.
However, the future improvement of combined biology
and modern radiotherapy technologies depends on a
constant, intense effort based on interdisciplinary and
international collaborations between all the fields
involved in (radiation) oncology.
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